Twist in Piazza Affari: the debut on the price lists of Rottapharm, expected for mid-July, will not be there. There Fidim Family Ruin yourself has withdrawn the global sale offer.
The shareholder of the pharmaceutical company, "in agreement with the coordinators of the global sales offer and the placement manager - reads a note - believes that the conditions for an operation that today reflects the value intrinsic to the Company, also in the light of the unfavorable situation of the domestic and international securities market which has led to a sudden change in investors' expectations on European assets and in particular in Southern Europe”.
The company confirms that "it will continue its path of growth, innovation and value creation, based on a clear and defined strategic direction supported by its proven capital solidity and its high financial and income capacity".
Rottapharm is the first of the large companies expected at Piazza Affari to have stopped listing in the last period after the Fincantieri IPO encountered more difficulties than expected.
